“...pleasure and pain, they come and go and don't last... bear them patiently”
—Gita
Pathos InvestmentsEquity Research
Research  ›  Fact Sheets  ›  COR

CENCORA, INC.

LISTEDNYSE
SYMBOLCOR
SIC5122
STATE OF INC.DE
FISCAL YEAR ENDSSeptember 30
CIK1140859

WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRIES · LARGE ACCELERATED FILER · 10 FISCAL YEARS OF SEC XBRL DATA, 2016–2025

REVENUES, NET INCOME AND FREE CASH FLOW BY FISCAL YEAR$ billions-10001002003004002016201720182019202020212022202320242025RevenuesNet incomeFree cash flowEARNINGS AND DIVIDENDS PER SHARE$ per share-20.00-10.000.0010.002016201720182019202020212022202320242025EPS dilutedDividends per share

Fiscal years labelled by the calendar year in which they end. Bars in $ billions; per-share figures as reported.

CAPITALIZATION 9/30/25

($ millions)Amount%
Total debt7,66183.6
Stockholders' equity1,50816.4
Total capitalization9,169100.0

190,827,165 shares outstanding at 31 July 2026 (cover page of the 10-Q filed 5 August 2026).

LONG-TERM DEBT 9/30/25

($ millions)Amount
Long-term debt, incl. current maturities7,661
Long-term debt, noncurrent7,543
Current maturities118

CAPITAL STOCK 9/30/25

Common shares authorized600,000,000
Common shares issued297,401,863
Treasury shares103,464,190
Par or stated value per share ($)0.01
Outstanding at 7/31/26190,827,165

DIVIDENDS DECLARED/PAID

Fiscal yearPer share $Payout %
20252.2027.6
20242.0427.1
20231.9422.7
20221.8422.9
20211.7623.8

HISTORY AND BUSINESS

HISTORY: Incorporated in Delaware. Formerly known as AMERISOURCEBERGEN CORP (to 15 August 2023); AMERISOURCE BERGEN CORP (to 9 October 2001).

BUSINESS: Classified by the SEC under Standard Industrial Classification 5122, Wholesale-Drugs, Proprietaries & Druggists' Sundries. Large accelerated filer. Principal executive office: 1 West First Avenue, Conshohocken, PA 19428. Fiscal year ends September 30. For a description of the business, see Item 1 of the latest 10-K.

CONSOLIDATED INCOME ACCOUNT, YEARS ENDED

($ millions)9/30/259/30/249/30/23
Revenues321,333293,959262,173
Cost of revenues309,854284,049253,214
Gross profit11,4799,9108,959
Selling, general and administrative6,4945,6615,310
Depreciation and amortization1,0511,092964
Operating income2,6292,1752,341
Income before income taxes2,2582,0042,161
Income taxes691485428
Net income1,5541,5091,745
Earned per share, diluted ($)7.967.538.53
Dividends per share ($)2.202.041.94

CONSOLIDATED BALANCE SHEET

($ millions)9/30/259/30/24
Cash and equivalents4,3563,133
Receivables, net25,22523,872
Inventories20,49218,999
Total current assets52,23947,718
Property, plant and equipment, net2,5392,181
Goodwill13,6779,318
Total assets76,59067,102
Total current liabilities57,82154,277
Long-term debt7,5433,812
Stockholders' equity1,508646
Total liabilities and equity76,59067,102

TEN-YEAR STATISTICS: FISCAL YEARS ($ millions except per share)

Fiscal year endedRevenuesOper. incomeNet incomeNet margin %EPS diluted $Div. per share $Oper. cash flowCapital expend.Free cash flowTotal assetsTotal liabilitiesTotal debtStockholders' equityROE %Debt / equity
9/30/25321,3332,6291,5540.57.962.203,8756683,20776,59074,843d7,6611,508103.15.08
9/30/24293,9592,1751,5090.57.532.043,4854872,99867,10266,315d4,388646233.66.79
9/30/23262,1732,3411,7450.78.531.943,9114583,45362,55961,892d4,787522334.39.17
9/30/22238,5872,3661,6990.78.041.842,7034962,20756,56156,489d5,703(212)-803.0-26.96
9/30/21213,9892,3541,5400.77.391.762,6674382,22857,33856,753d6,684223689.529.93
9/30/20189,894(5,135)(3,409)-1.8(16.65)1.662,2073701,83744,27545,114d4,120(1,019)334.5-4.04
9/30/19179,5891,1128550.54.041.602,3443102,03439,17236,179d4,1732,87929.71.45
9/30/18167,9401,4441,6581.07.531.521,4113361,07537,67034,620d4,3102,93356.51.47
9/30/17153,1441,0603640.21.641.461,5044661,03835,31633,252d3,4422,06417.71.67
9/30/16146,8501,5261,4281.06.321.363,1784652,71433,63831,508d4,1872,12967.11.97

Net margin = net income ÷ revenues; ROE = net income ÷ year-end stockholders’ equity; total debt = long-term debt including current maturities plus short-term borrowings/commercial paper, as tagged in XBRL; free cash flow = operating cash flow − purchases of property, plant and equipment; d = derived as total assets − total equity where the filing does not tag total liabilities; – = not reported in XBRL for that year.

REGISTRANT:

Cencora, Inc.
CIK 1140859 · EIN 23-3079390

PRINCIPAL OFFICE:

1 West First Avenue, Conshohocken, PA 19428
Tel.: 610-727-7000

INCORPORATED:

Delaware

INDUSTRY (SEC SIC CODE):

5122 · Wholesale-Drugs, Proprietaries & Druggists' Sundries

FILER STATUS:

Large accelerated filer

LATEST ANNUAL REPORT:

10-K for period ended 9/30/25, filed 25 November 2025

FORMER NAMES:

AMERISOURCEBERGEN CORP; AMERISOURCE BERGEN CORP

RECENT FILINGS (ANNUAL REPORT REFERENCES BELOW):

9/25/268-Kperiod 9/24/26
8/14/268-Kperiod 8/13/26
8/12/268-Kperiod 8/12/26
8/5/2610-Qperiod 6/30/26
8/5/268-Kperiod 7/31/26
8/5/268-Kperiod 8/5/26
6/15/268-Kperiod 6/10/26
5/29/268-Kperiod 5/23/26

Sources: SEC XBRL company facts (all financial figures) · SEC submissions (registrant, address, SIC, filings) · annual reports: 10-K FY2025 (filed 11/25/25) · 10-K FY2024 (filed 11/26/24) · 10-K FY2023 (filed 11/21/23) · 10-K FY2022 (filed 11/22/22) · 10-K FY2021 (filed 11/23/21) · 10-K FY2020 (filed 11/19/20) · 10-K FY2019 (filed 11/19/19) · 10-K FY2018 (filed 11/20/18). Values are the latest figures filed for each fiscal year (restated where a later 10-K restated them). Ratios and free cash flow are Pathos calculations from those figures. Retrieved 31 October 2026.

Data from SEC filings. © 2026 Pathos Investments · pathosinvestments.com · For educational purposes only. Not investment advice.

Data from SEC filings  ·  Educational only  ·  Not investment advice